Figure 3

EHD2 downregulation is associated with breast cancer cell aggressiveness. (a–c) Representative transmitted light images (left) and quantification (right) of cell migration using a wound healing assay in Hs578T cells EHD2 depleted (siEHD2) or not (CTRL) (a), in MDA-MB-231 cells overexpressing EHD2 or not (CTRL) (b), and in MDA-MB-436 cells overexpressing EHD2 or not (CTRL) (c). Scale bar =10 μm. Cell migration into the wound site was assessed after 16 h. (d–f) Quantification of invasion using Transwell chamber inserts in Hs578T cells EHD2 depleted (siEHD2) or not (CTRL) in the absence (negative control) or presence of serum (d), in MDA-MB-231 cells overexpressing EHD2 or not (CTRL) (e), and in MDA-MB-436 cells overexpressing EHD2 or not (CTRL) (f). (g) Measurement of cell proliferation of the Hs578T cells EHD2 depleted (siEHD2) or not (CTRL), and in MDA-MB-436 cells overexpressing EHD2 or not (CTRL). (h,i) Quantification of IL-8 mRNA levels in Hs578T cells EHD2 depleted (siEHD2) or not (CTRL) (h), and in MDA-MB-231 cells overexpressing EHD2 (i); n ≥ 3 independent experiments; ns = non-significant; *P < 0.05; **P < 0.01; (a–c,e–i) two tailed t-test; (d) Bonferroni’s multiple comparison test; mean ± s.e.m.